Enanta Pharmaceuticals, Inc.
ENTA
$11.44
$0.090.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.37% | 0.58% | -3.42% | -9.94% | -11.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.37% | 0.58% | -3.42% | -9.94% | -11.55% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.37% | 0.58% | -3.42% | -9.94% | -11.55% |
| SG&A Expenses | -25.43% | -25.99% | -24.06% | -17.34% | -10.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.20% | -20.85% | -20.42% | -17.04% | -20.02% |
| Operating Income | 40.86% | 33.79% | 29.86% | 21.20% | 24.58% |
| Income Before Tax | 37.42% | 31.66% | 29.07% | 20.36% | 23.87% |
| Income Tax Expenses | 103.71% | 20.62% | 4.76% | 26.34% | -235.76% |
| Earnings from Continuing Operations | 35.71% | 31.82% | 29.43% | 20.22% | 26.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.71% | 31.82% | 29.43% | 20.22% | 26.81% |
| EBIT | 40.86% | 33.79% | 29.86% | 21.20% | 24.58% |
| EBITDA | 43.96% | 36.78% | 32.33% | 22.69% | 25.50% |
| EPS Basic | 42.85% | 35.29% | 30.03% | 20.82% | 27.32% |
| Normalized Basic EPS | 43.74% | 34.55% | 29.95% | 22.19% | 25.45% |
| EPS Diluted | 42.85% | 35.29% | 30.03% | 20.82% | 27.32% |
| Normalized Diluted EPS | 43.74% | 34.55% | 29.95% | 22.19% | 25.45% |
| Average Basic Shares Outstanding | 18.34% | 9.54% | 0.86% | 0.79% | 0.71% |
| Average Diluted Shares Outstanding | 18.34% | 9.54% | 0.86% | 0.79% | 0.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |